MedTrace Logo

Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study

NCT05227456 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-11-25

No results posted yet for this study

Summary

The objective of this study is to assess the efficacy of an implantable etonogestrel device in reducing hysterectomy rate in patients with a failed endometrial ablation.

Conditions

  • Abnormal Uterine Bleeding
  • Dysmenorrhea

Interventions

DRUG

Etonogestrel 68mg implant

Implant will be inserted

DEVICE

Etonogestrel 68mg implant

Implant will be inserted

Sponsors & Collaborators

  • University of Saskatchewan

    collaborator OTHER

  • Saskatchewan Health Authority - Regina Area

    lead OTHER

Principal Investigators

  • Sarah N Smith, MD · Obstetrician Gynecologist

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2024-04-30
Completion
2024-04-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05227456 on ClinicalTrials.gov